Fundz

In8bio reported raising $35 Million in an initial SEC Form D filing, from an offering of $14.4 Million

PUBLIC · INABDec 28, 2023

Amount Raised

$35 Million

$35 Million sold, per SEC Form D (first sale Dec 13, 2023)

Round Type

Venture

New YorkBiotechnologyTherapeutics

Who to call at IN8bio, and when

A new round usually means IN8bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day IN8bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at IN8bio, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

IN8bio

Location

New York, New York, United States

About

IN8bio is a clinical-stage biopharmaceutical company advancing gamma-delta T cell therapies for the treatment of cancer, leveraging its proprietary DeltEx platform to develop ex vivo–expanded, activated, and genetically modified cell therapies using allogeneic and autologous approaches. As the most clinically advanced company in this field, IN8bio combines deep expertise in gamma-delta T cell biology, genetic engineering, and specialized manufacturing to design novel therapies that precisely identify and eradicate tumor cells.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment IN8bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts12 people are listed at IN8bio. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for IN8bio's next move

See what Strategic adds

IN8bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.